Educating patients on the “risks and benefits” of clinical trials is a part of the pipeline for better treatment options in myeloproliferative neoplasms (MPNs) in which nurses can engage, said a nurse ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

According to a nurse practitioner who works in myeloma research, nurses and APPs are responsible for much of the clinical work with patients involved in trials.

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with ...

Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib. Adding daratumumab (Darzalex) to bortezomib ...

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

Real-World Data Shows Apalutamide Increases 24-Month OS in mCSPC ...

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Panelists discuss how cardiovascular toxicity remains a significant concern with certain tyrosine kinase inhibitors (TKIs) used in chronic myeloid leukemia (CML) treatment, particularly with the older ...